Literature DB >> 32787434

Lamin B1 deficiency promotes malignancy and predicts poor prognosis in gastric cancer.

Z Y Yu1, X Y Jiang1, R R Zhao2, C J Luo1, Y X Ren1, Z J Ma3, H L Ye3, W G Shi3, C Wang1, Z Y Jiao1,3.   

Abstract

Gastric cancer (GC) is a kind of global malignancy. However, the expression pattern and clinical relevance of lamin B1 in GC remain to be elucidated. We endeavored to investigate how GC is influenced by lamin B1 and the related mechanisms. The lamin B1 expression in GC tissues from 71 patients was assessed by using immunohistochemistry (IHC). The expression of lamin B1 was connected with the clinical stage, depth of invasion, and poorer overall survival. Colony formation assays and methyl thiazolyl tetrazolium (MTT) were used to assess cell viability. The migration ability of GC cells was determined by cell scratch assay and Transwell invasion assay. Moreover, we used two cell lines of GC to explore the underlying mechanism of lamin B1 in boosting the GC cells proliferation and invasion in vitro by assessing the effects on related signal transduction pathways. Our data demonstrated that the expression level of lamin B1 was downregulated in GC tissues, and low expression level of lamin B1 was significantly correlated with higher clinical stage, depth of invasion, nodal stage, and poor prognosis. Moreover, in vitro experiments demonstrated that lamin B1 knockdown promoted, whereas lamin B1 overexpression inhibited, gastric cancer cell proliferation and migration. We also observed that lamin B1 knockdown could promote the activity of the PI3K/PTEN/Akt and MAPK/ERK pathway with a decrease in the p53/p21WAF1/CIP1 expression, whereas lamin B1 overexpression contributed to the opposite results. In conclusion, our studies indicate that lamin B1 deficiency is crucial in GC progression. Furthermore, the results elucidating the biological mechanisms of lamin B1 may potentially contribute to current GC treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32787434     DOI: 10.4149/neo_2020_200109N33

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  3 in total

1.  The Expression of the Senescence-Associated Biomarker Lamin B1 in Human Breast Cancer.

Authors:  Tareq Saleh; Ahmad Alhesa; Mohammed El-Sadoni; Nisreen Abu Shahin; Elham Alsharaiah; Sofian Al Shboul; Heyam Awad; Sarah Bloukh; Mahmoud Al-Balas; Mohammad Alsalem; Bilal Azab; Tariq N Aladily
Journal:  Diagnostics (Basel)       Date:  2022-02-28

2.  Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancers.

Authors:  Haixiang Qin; Yingqiang Lu; Lin Du; Jingyan Shi; Haoli Yin; Bo Jiang; Wei Chen; Wenli Diao; Meng Ding; Wenmin Cao; Xuefeng Qiu; Xiaozhi Zhao; Hongqian Guo
Journal:  Cancer Cell Int       Date:  2022-03-03       Impact factor: 5.722

Review 3.  The wide and growing range of lamin B-related diseases: from laminopathies to cancer.

Authors:  Camilla Evangelisti; Isabella Rusciano; Sara Mongiorgi; Giulia Ramazzotti; Giovanna Lattanzi; Lucia Manzoli; Lucio Cocco; Stefano Ratti
Journal:  Cell Mol Life Sci       Date:  2022-02-08       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.